NCT00746317 - A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2012

Conditions

Advanced or Metastatic HCC

Interventions

DRUG

GC33

IV administration at 4 escalating dose levels.

Trial Locations (9)

Columbia University Medical Center, New York

Karmanos Cancer Center at the Detroit Medical Center, Detroit

Washington University, St Louis

Methodist Hospital, Houston

USC/Norris Comprehensive Cancer Center, Los Angeles

Swedish Cancer Institute at the Swedish Medical Center, Seattle

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston